News
But three of those FDA employees told CNN that Elsa just makes up nonexistent studies, something commonly referred to in AI ...
6d
Futurism on MSNThe FDA Is Using an AI to "Speed Up" Drug Approvals and Insiders Say It's Making Horrible MistakesInsiders at the Food and Drug Administration are ringing alarm bells over the agency's use of an AI to fast-track drug ...
Insiders tell CNN the FDA’s AI is “hallucinating” studies and can’t access key documents. Agency leaders insist the AI is ...
FDA officials say the assistant is flawed, just as the Trump administration stresses AI adoption in healthcare.
2h
News-Medical.Net on MSNAI uncovers new lipid-lowering effects in existing FDA-approved drugsIn a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected ...
While the FDA is not commenting about how far it might use AI tools in speeding up the drug and device review process, some experts say that the agency so far seems to be focusing on ...
The Food and Drug Administration (FDA) is looking to AI to solve the problem of lengthy approval processes, as the Trump administration invests in even more automation amid thousands of federal ...
6d
Que.com on MSNAI in FDA Drug Approvals Sparks Controversy Over Fabricated StudiesIn recent years, Artificial Intelligence (AI) has made significant strides across various sectors, providing innovative solutions and enhancing efficiency. However, ...
Hosted on MSN2mon
FDA, OpenAI discussing use of AI for drug evaluation - MSNThe FDA already has ways to speed up the approval process for promising drugs, such as fast track and breakthrough therapy designations. AI could add another layer of efficiency, but it must be ...
7dOpinion
The New Republic on MSNRFK Jr. Is Letting AI Help Run the FDA. There’s Just One ProblemHallucinations are a known problem with generative AI models—and Elsa is no different, according to Jeremy Walsh, the head of ...
The FDA becomes involved before any new drug molecule is tested in humans. Here’s how upheaval at the agency appears to be affecting specific points in the approval process for new drugs.
Researchers from Southern Medical University and collaborators report the identification of FDA‑approved compounds that may ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results